Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2020 · 10-Q
Revenue$1.01M$1.01M+230.8% vs Q3 2019 Net Income-$2.08M-$2.08MN/M vs Q3 2019 EPS Diluted-$0.04-$0.04N/M vs Q3 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,499,347N/M Free Cash Flowderived-$2,503,601N/M Margins · derivedGross margin34.1%+38.6 pt vs Q3 2019
Operating margin-214.3%+68.0 pt vs Q3 2019
Net margin-206.4%−188.7 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end